Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.01
5% from low
Exchange
OTC Link
CS
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $2.7M | $1.6M | $1.1M | $1.0M | $1.4M | $863.8K | $986.2K |
| Cost of revenue | $1.2M | $917.9K | $584.3K | $322.2K | $451.3K | $360.7K | $358.3K | $383.0K |
| Gross profit | $1.2M | $1.8M | $1.0M | $742.2K | $578.6K | $1.0M | $505.6K | $603.2K |
| Gross margin | 50.3% | 66.0% | 63.6% | 69.7% | 56.2% | 74.4% | 58.5% | 61.2% |
| R&D | $8.4K | $1.9K | $120 | $0 | $0 | $14.6K | $0 | $152 |
| Operating income | −$1.1M | −$300.8K | −$717.4K | −$479.6K | −$32.2K | $317.5K | −$283.0K | −$122.9K |
| EBITDA | −$915.0K | $69.3K | $2.2M | −$766.6K | −$101.7K | −$153.6K | −$1.4M | −$215.2K |
| Net income | $844.4K | −$54.6K | $2.1M | −$854.3K | −$163.1K | −$257.2K | −$1.5M | −$274.4K |
| Net margin | 35.8% | -2.0% | 132.7% | -80.3% | -15.8% | -18.3% | -173.0% | -27.8% |
| EPS (diluted) | 0.04 | -0.00 | 0.11 | -0.04 | -0.01 | -0.01 | -0.07 | -0.01 |
Annual figures · source: Financial Modeling Prep
REMEDENT INC
No one on the platform currently holds REMI.
No tracked institution reports a position in REMI as of their last filing.
No one on the platform has traded REMI yet.
| $4035 |
| — |
| NMXSNet Medical Xpress Solutions, Inc. | $0.00 | +0.00% | $26367 | — |
| THCTTHC Therapeutics, Inc. | $0.00 | +0.00% | $34980 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.0× sales vs its 2.4× historical median P/S.
Fair value ≈ $0.10 · price $0.00 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.